News

AMRI expects its $41M Cedarburg deal to pay off right away

AMRI has wrapped up its $41 million effort to acquire contract manufacturer Cedarburg Pharmaceuticals, and the company says it's in line for an immediate windfall.

Actavis picks Particle Sciences for generics development

Contract developer Particle Sciences has nailed down a deal with Actavis, lending its drug delivery expertise to the generics giant. 

WuXi bets on anti-counterfeiting tech with an eye on drug safety

WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.

Clinipace signs up to get a brain-stimulating device on the U.S. market

Global CRO Clinipace has agreed to manage clinical trials for Nexstim as the Finnish devicemaker works toward FDA approval for its neurostimulation therapy.

BioClinica bags $30M in Big Pharma deals

CRO BioClinica said it inked two long-term deals with major drugmakers totaling $30 million, touting its eClinical technology as driving sponsor interest.

Rho inks a federal bioterror pact with $100M on the line

North Carolina CRO Rho has signed up to help the U.S. government's Biomedical Advanced Research and Development Authority design and conduct clinical trials for treatments that protect against bioterrorism and other public health emergencies, getting in line for as much as $100 million over 5 years.

NephroGenex picks Medpace for kidney disease Phase III

A month removed from a $915 million buyout deal, CRO Medpace has signed on to help biotech NephroGenex get through Phase III with its promising kidney disease candidate.

Quintiles signs on to help BioDelivery get its anti-addiction drug out the door

Raleigh, NC's BioDelivery Sciences is expecting to win FDA approval for its opioid-dependence patch this summer, and the biotech has enlisted global contractor Quintiles to handle the launch.

Icon is buying Aptiv with a focus on adaptive trials

CRO giant Icon has agreed to trade $143.5 million for Aptiv Solutions, looking to complement its own technology in complex trial design and expand its presence in Japan.

Covance dials up its biologics offerings, adding 100 new jobs

Global CRO Covance is expanding its heft in biologics development, plotting to double its capacity over the next 5 years.

CMO Recipharm plots a $142M Swedish IPO

Amid the prolonged bull market for life sciences IPOs, a handful of European firms are lining up to test the waters in Europe, including CMO giant Recipharm, which is planning to stage a $142 million offering.

TKL cuts the ribbon on a new Phase I operation

Contract outfit TKL Research has opened a new early-phase-focused clinic in Northern New Jersey, looking to capitalize on demand for Phase I services as it expands its footprint.

AMRI bets on manufacturing with $41M Cedarburg buyout

AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.

Risk-sharing researcher Evotec buys an academic pipeline

Germany's Evotec has signed a deal to buy up a biopharma asset management company and get its hands on some promising drug candidates, broadening its novel approach to the CRO game by adding some unpartnered assets to its stable of collaborations.

Parexel eyes Asian trials with Singapore expansion

Parexel is stretching its global network of clinical trial supply operations with a new distribution center in Singapore, bringing the facility online to better support studies across the globe.

GVK plots a $16.5M Indian expansion as it dials up its global presence

Indian CRO GVK Biosciences is looking to boost its capabilities in contract manufacturing, planning to build a new plant in its home country while stretching its presence abroad.

Meet DPx, the result of a $2.6B CMO merger

A $2.6 billion deal united contract manufacturers Patheon and DSM Pharmaceutical Products, and now the combined company has emerged to do business under the monicker DPx, expecting to bank $2 billion in revenue this year.

Post-merger BioClinica looks to corner the imaging market

BioClinica has come out the other side of its second merger in as many years, absorbing CCBR-Synarc and plotting to shift its focus toward medical imaging and specialty services for clinical trials.

PPD lands a federal bioterror deal worth up to $100M

PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.

Charles River snaps up Galapagos' CRO biz for $179M

Charles River Laboratories is looking to pad its preclinical prowess, inking a $179 million deal with drugmaker Galapagos for two CRO subsidiaries and a chance to expand its in vitro biology expertise.